· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease

https://thesicktimes.org/2026/02/17/research-updates-february-17/

#ResearchUpdates #COVID

· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease

https://thesicktimes.org/2026/02/17/research-updates-february-17/

#ResearchUpdates #COVID

· A large study recently connected “chronic absenteeism” to pediatric #LongCOVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic
· A small mechanistic study in Brain, Behavior, & Immunity – Health found that immunoglobulin G (IgG), isolated from people with #MECFS, can destroy mitochondria in endothelial cells
· ADDRESS-LC has opened two more study sites: a new one in California and one in Connecticut

https://thesicktimes.org/2026/02/10/research-updates-february-10/

#ResearchUpdates

· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome ( #POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)

https://thesicktimes.org/2026/02/03/research-updates-february-3/

#ResearchUpdates #COVID

· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda

https://thesicktimes.org/2026/01/27/research-updates-january-27/

#ResearchUpdates

· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research

https://thesicktimes.org/2026/01/20/research-updates-january-20/

#ResearchUpdates

· A large, electronic health records study published in JAMA Internal Medicine estimated that over 100,000 Americans died each year between 2022 and 2024 from #COVID19
· A new study published in Molecular & Cellular Proteomics found further evidence of abnormalities in post-exertional malaise #PEM
· A small phase two clinical trial is testing #Ketamine for #LongCOVID fatigue and cognitive function

https://thesicktimes.org/2026/01/13/research-updates-january-13/

#ResearchUpdates #TheSickTimes

· 43% of Latino people reported symptoms of #LongCOVID in a new survey study published in Journal of General Internal Medicine
· A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology
· A new phase II clinical trial for Long COVID was recently announced in the Netherlands

https://thesicktimes.org/2026/01/06/research-updates-january-6/

#ResearchUpdates #COVID

· Two recent studies state that #LongCOVID is an occupational disease.
· Vanderbilt researchers are conducting an immune profiling study on people with Long COVID and postural orthostatic tachycardia syndrome ( #POTS)
· A new phase two remote clinical trial was recently announced for myalgic encephalomyelitis (ME) #MECFS

https://thesicktimes.org/2025/12/23/research-updates-december-23/

#ResearchUpdates

· New study in Cureus found veterans diagnosed with #LongCOVID at 34% higher risk of visiting emergency department 6 months after infection
· “Our data demonstrate that [LC] is characterized by chronic inflammation, immune exhaustion, & metabolic dysregulation,” scientists conclud in new study published in Nature Immunology
· U.K. charity ME Association awards £1.1 million in funding to the Imperial College to study immunological profiles of LC & #MECFS

https://thesicktimes.org/2025/12/16/research-updates-december-16/

#ResearchUpdates

· A new study in the International Journal of Infectious Diseases examines how #COVID19 impacts the immune system
· German government announced just over €500 million ($582 million USD) in funding for infection-associated diseases, including #LongCOVID & #MECFS
· A preprint using data from the DecodeME study found more than 250 genes associated with ME, 76 of which were shared with Long COVID

https://thesicktimes.org/2025/12/09/research-updates-december-9/

#researchupdates

· Large retrospective cohort study of over 18,000 births found infants exposed to #COVID19 during pregnancy were more likely to have adverse neurodevelopmental diagnoses as 3 years olds
· Another study has found that common diabetes drug metformin may help reduce risk of #LongCOVID
· NIH is recruiting for a small observational study to understand if people with neurological symptoms of Long COVID have inactive [?] remnants of SARS-CoV-2 in their bodies

https://thesicktimes.org/2025/12/02/research-updates-december-2/

#ResearchUpdates

· A review paper summarizes the vast global costs of #LongCOVID, it is estimated to have an average annual burden of at least $1 trillion globally per year
· A small study in Nature found SARS-CoV-2 in the organs of fetuses from people who were infected with the virus while pregnant
· The National Institutes of Health’s RECOVER-Treating Long COVID initiative released a draft of its protocol for the low-dose naltrexone trial for people ages 6-25

https://thesicktimes.org/2025/11/25/research-updates-november-25/

#ResearchUpdates #covid19

arXiv No Longer Accepts Computer Science Position or Review Papers Due to LLMs

https://blog.arxiv.org/2025/10/31/attention-authors-updated-practice-for-review-articles-and-position-papers-in-arxiv-cs-category/

#HackerNews #arXiv #LLMs #ComputerScience #ResearchUpdates #AcademicPublishing

· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis ( #ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311

https://thesicktimes.org/2025/09/16/research-updates-september-16/

#COVID19 #ResearchUpdates

· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure

https://thesicktimes.org/2025/09/09/research-updates-september-9/

#ResearchUpdates

· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10

https://thesicktimes.org/2025/09/02/research-updates-september-2/

#ResearchUpdates #COVID19

· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine

https://thesicktimes.org/2025/08/19/research-updates-august-19/

#ResearchUpdates

· People with myalgic encephalomyelitis ( #MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida

https://thesicktimes.org/2025/08/12/research-updates-august-12/

#ResearchUpdates #COVID19